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Introduction

Background

Opioid misuse has become
increasingly significant in
expecting mothers over the years.
Doctors and researchers have
created data charts to further
investigate the use of opioid
management therapies such as
Methadone and Buprenorphine to
combat Neonatal Abstinence
Syndrome and determine the
long-term effects it would have on
a developing child (Kaltenbach et
al., 2018).
• The purpose of these studies
were to determine how the
management therapies would
affect infant development
(Handal et al., 2019.)

• The studies focused on
determining the development of the
infant and the effects it would have
on cognition, sensory perception,
and the duration of the hospital
stay in correlation to the opioid
management therapy underwent in
utero (Kaltenbach et al., 2019)
• Infant development would be
measured on the Neonatal
Abstinent Syndrome Scale
(Wachman et al., 2018) as well as
using the Mother scale (Kaltenbach
et al., 2019)
• Opioid Management Therapies
were used to conclude the
differences in infants undergoing
treatment to those who did not in
utero (Sebastini et al., 2018).

Purpose
Expecting mothers who misused
opioids during pregnancy underwent
opioid management therapies to
determine long-term effects on the
development of the infant in
comparison to expecting mothers
misusing opioids and not undergoing
treatment (Sebastini et al., 2018).
Researchers expected the outcome
to greatly influence no harmful
defects on the infants who
experienced management treatment
in utero for the duration of the
pregnancy until three years of age
(Handal et al., 2019).

Literature Review Methods
East Tennessee State University
Sherrod Library was used to search in
databases such as PubMed and
CINAHL for 5 articles pertaining to
Opioid Management Therapy. The CDC
was further used to determine a more
in-depth need for management therapy.
• Key words: “Opioid Management”,
“fetal development”, “Neonatal
Abstinent Syndrome therapy”,
“Methadone therapy in utero”

Significant Findings
• A study of 175 women was
conducted to provide substantial
evidence that the use of
Buprenorphine and Methadone
had no harmful lasting effects on
infants up to age three when used
as an opioid treatment therapy
(Kaltenbach et al., 2018).

• Nursing Interventions were put
into the research to determine if
both pharmacologic treatment
such as Methadone and nonpharmacologic treatment such as
staying in the room with the
mother after delivery would
conclude a positive fetal
development (Wachman et l.,
2018). This study concluded that
there was a 20-60% decrease in
hospital stay for the infant
(Wachman et al., 2018).

Conclusion
The need for more education for women
undergoing opioid management therapy
is evident within the research provided
(Sebastini et al., 2018). The use of
Methadone and Buprenorphine have
been concluded useful in the treatment of
women misusing opioids during
pregnancy and have a positive affect on
infant development through 36 months of
age (Kaltenbach et al., 2018).
• Furthermore, to conclude the research,
the CDC recommends the use of both
Methadone and Buprenorphine as an
adequate first-line of defense treatment
in the fetal development in utero and
during the first few years of growth
(CDC, 2021).

• In the study from Handal et al,
2019 it was found to have similar
results from women who
underwent the maintenance
therapy and those who did not,
both groups that were researched
had infants with similar
development.
• Similarly in another study while
there was no substantial
difference in treatment or no
treatment, researchers found that
infants who did not receive
treatment were born with greater
risk for withdraw toxicity
(Sebastini et al., 2018).
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